<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922467</url>
  </required_header>
  <id_info>
    <org_study_id>2008/47</org_study_id>
    <nct_id>NCT00922467</nct_id>
  </id_info>
  <brief_title>Influence of Esmolol on a Closed-Loop Anesthesia System</brief_title>
  <official_title>Closed-loop Delivery of Propofol and Remifentanil: Sparing Effect of Esmolol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective is to evaluate the sparing effect of esmolol on the required doses of propofol
      and remifentanil
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of effectiveness
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>administered doses of propofol and of remifentanil during anesthesia</measure>
    <time_frame>end of anesthesia</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>delay before recovery</measure>
    <time_frame>at the end of anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemodynamic abnormalities requiring a treatment</measure>
    <time_frame>end of anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative morphine requirement</measure>
    <time_frame>Third post-anesthetic hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>explicit memorisation</measure>
    <time_frame>Second postoperative day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and esmolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 9/00</intervention_name>
    <description>Same volume as in the esmolol group</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period</description>
    <arm_group_label>Esmolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male patients scheduled for a general anesthesia

        Exclusion Criteria:

          -  age lower than 18 years

          -  allergy to propofol, or to soja or to peanuts, or to sufentanil, to remifentanil, or
             to morphine, or to a myorelaxant or to an excipient,

          -  any other history of anaphylactic reaction,

          -  hypersensibility to sufentanil, or to remifentanil, or to other derivate of fentanyl,

          -  hypersensibility to esmolol or to an excipient,

          -  history of central nervous system disease,

          -  patients receiving a psychotropic treatment or an agonist-antagonist opiate,

          -  hypovolemic patients,

          -  patients receiving a cardio-vascular treatment,

          -  patients with a pacemaker,

          -  expected bleeding more than 20% of the blood volume,

          -  simultaneous general and loco-regional anesthesia,

          -  patients suffering from asthma, COPD, trouble of the heart rhythm or conduction,
             cardiac insufficiency, cardiogenogenic shock, Prinzmetal syndrome, pheochromocytoma,

          -  patients with a heart rate less than 50/min and/or an arterial hypotension,

          -  neurosurgical act or any other which precludes an adequate positioning of the
             bispectral electrode.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Fischler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Foch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

